Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma 2Ovarian Neoplasms 1Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Peripheral Blood Stem Cell Transplantation 32fludarabine phosphate 29Cyclophosphamide 26Whole-Body Irradiation 21Cyclosporine 20Busulfan 20Mycophenolic Acid 19Tacrolimus 16Antilymphocyte Serum 14Methotrexate 13romidepsin 12Etoposide 12Filgrastim 11Melphalan 9Psychiatric Rehabilitation 8Methylprednisolone 8Dexamethasone 8Bexarotene 8Vorinostat 7Flow Cytometry 7Therapeutics 6Radiotherapy 6Calcium Dobesilate 6Brentuximab Vedotin 6Bortezomib 6Alemtuzumab 6sargramostim 5fludarabine 5denileukin diftitox 5Polymerase Chain Reaction 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, T-Cell, Cutaneous × quisinostat × Clear all
NCT01486277 2016-11-03

A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma

Janssen Research & Development, LLC

Phase 2 Completed
26 enrolled
DermatologicLymphoid

Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡